In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
first published: Jul 21, 2011 03:55 pm
A collection of the most-viewed Moneycontrol videos.
The Lawyer Renting in one of Mumbai’s most green societies | The Tenant
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
